Teva Pharmaceutical reported strong first-quarter 2026 results, driven by a 41% year-over-year revenue increase to $838 million from its innovative neuroscience drugs AUSTEDO, AJOVY, and Uzedy. This growth offset declines in its legacy generics business. The company maintained its full-year guidance, with stable gross margins at 52.9% and aims to achieve a 30% non-GAAP operating income margin by 2027. Additionally, Teva's pipeline is gaining credibility, biosimilars are progressing, and the upcoming acquisition of Emalex is expected to add further growth opportunities.
Ether has surged about 11% over the past week, outperforming other major cryptocurrencies like Bitcoin, which rose 4%. This rise is driven by $96 million inflows into U.S. spot ether ETFs, mainly BlackRock’s low-fee funds, while Grayscale’s higher-fe...
Veea Inc. has announced the commercial release of VeeaONE, a full-stack AI infrastructure platform that integrates edge-to-cloud hardware and software. The platform supports VeeaWare middleware on NVIDIA Jetson and x86/Arm servers, enabling secure, l...
Virtuals Protocol has introduced customizable tokenized indexes on the Robinhood Chain, allowing users to combine multiple assets into a single token. This innovation enables users to create and manage their own asset baskets and earn fees when other...
US spot Bitcoin ETFs saw net inflows of $107.8 million on Wednesday, while Ethereum ETFs attracted $53.8 million, signaling renewed institutional interest in crypto funds. Since their launch in January 2024, Bitcoin ETFs have accumulated over $51 bil...
Kaia has signed a strategic partnership with Xilo Labs to integrate Mochi, an onchain asset management platform, into Kaia's ecosystem. This collaboration allows users to invest stablecoins into diversified portfolios backed by tokenized real-world a...
